Evidence map›Paper›PMID 40215398›Full record

Trial reportJMIR cardio2025

A Web-Based Tool to Perform a Values Clarification for Stroke Prevention in Patients With Atrial Fibrillation: Design and Preliminary Testing Study.

Michael P Dorsch, Allen J Flynn, Kaitlyn M Greer, Sabah Ganai, Geoffrey D Barnes, Brian Zikmund-Fisher

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in JMIR cardio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael P DorschCollege of Pharmacy, University of Michigan, 248 Church Street, Ann Arbor, MI, 48109, United States, 17347647312.ORCID http://orcid.org/0000-0003-2910-1879
Allen J FlynnDepartment of Learning Health Sciences, Medical School, University of Michigan, Ann Arbor, MI, United States.ORCID http://orcid.org/0000-0002-3471-3063
Kaitlyn M GreerCollege of Pharmacy, University of Michigan, 248 Church Street, Ann Arbor, MI, 48109, United States, 17347647312.ORCID http://orcid.org/0009-0009-3921-7091
Sabah GanaiCollege of Pharmacy, University of Michigan, 248 Church Street, Ann Arbor, MI, 48109, United States, 17347647312.ORCID http://orcid.org/0000-0003-1338-8385
Geoffrey D BarnesDivision of Cardiovascular Medicine, Medical School, University of Michigan, Ann Arbor, MI, United States.ORCID http://orcid.org/0000-0002-6532-8440
Brian Zikmund-FisherSchool of Public Health, University of Michigan, Ann Arbor, MI, United States.ORCID http://orcid.org/0000-0002-1637-4176

Funding

AHRQ HHS R21 HS026322
6 · The paper itself

Abstract

Background: Atrial fibrillation (AF) is associated with an increased risk of stroke. Oral anticoagulation (OAC) is used for stroke prevention in AF, but it also increases bleeding risk. Clinical guidelines do not definitively recommend for or against OAC for patients with borderline stroke risk. Decision-making may benefit from values clarification exercises to communicate risk trade-offs. Objective: This study aimed to evaluate if a visual with a values clarification alters the understanding of the trade-offs of anticoagulation in AF. Methods: Participants aged 45-64 years were recruited across the United States via an online survey. While answering the survey, they were asked to imagine they were newly diagnosed with AF with a CHA2DS2-VASc (congestive heart failure; hypertension; age ≥75 years [doubled]; type 2 diabetes; previous stroke, transient ischemic attack, or thromboembolism [doubled]; vascular disease; age 65 to 75 years; and sex category) score of 1 for men and 2 for women. Eligibility criteria included no diagnosis of AF and no prior OAC use. Participants were randomized to one of three conditions: (1) standard text-based information only (n=255), (2) visual aids showing stroke-risk probabilities (n=218), or (3) visual aids plus a values clarification exercise (visual+VC; n=200). Participants were subrandomized within the 2 visual-based groups to view either a gauge display or an icon array representing stroke risk. All participants read a hypothetical scenario of being newly diagnosed with AF and hypertension. The primary outcome was decision confidence as measured by the SURE (Sure of Myself; Understand Information; Risk-Benefit Ratio; Encouragement) test. Secondary measures included participants' perceived stroke risk reduction, worry about stroke or bleeding, and likelihood to choose OAC. Results: A total of 673 participants completed the survey. The overall SURE test was 61.2% (156/255) for the standard, 66.5% (145/218) for the visual, and 67% (134/200) for the visual+VC group (visual vs standard P=.23; visual+VC vs standard P=.20). Participants were less likely to choose OAC in the visual groups (standard: mean 58.3, SD 30; visual: mean 51.4, SD 32; visual+VC: 51.9, SD 28; P=.03). Participants felt the reduction in stroke risk from an OAC was less in the visual groups (standard: mean 63.8, SD 22; visual: mean 54.2, SD 28; visual+VC: mean 58.6, SD 25; P<.001). Visualization methods (gauge vs icon array) showed no significant differences in overall SURE test results. Participants were less likely to choose OAC and perceived a smaller stroke risk reduction with gauge than icon array (OAC choice: gauge 48.8, icon array 55.4; P=.03; stroke risk reduction: gauge 52.1, icon array 60.4; P=.001). Conclusions: Visual aids can modestly affect decision confidence and perceptions regarding the benefits of OAC but do not significantly alter decision certainty in a scenario where the guidelines do not recommend for or against OAC. Future work should determine the role of a gauge versus icon array visual for decision-making in stroke prevention in AF.

Indexed as

AnticoagulantsAtrial FibrillationInternetStrokeAgedFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorsSurveys and QuestionnairesUnited StatesAnticoagulantsatrial fibrillationdigital healthshared decision-makingstroke preventionvalues clarification

Identifiers

PMID40215398
PMCPMC12007723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.